AZGP1 Up-Regulation is a Potential Target for Andrographolide Reversing Radioresistance of Colorectal Cancer.

Ye-Ying FangJin-Mei HuangJia-Ying WenJian-Di LiJin-Hai ShenDa-Tong ZengYan-Fang PanHe-Qing HuangZhi-Guang HuangLi-Min LiuGang Chen

Published in: Pharmacogenomics and personalized medicine (2022)

AZGP1 is recognized as a crucial factor for both CRC initiation and radioresistance. Andrographolide may affect the radioresistance of CRC via the targeting of AZGP1. Thus, the combination of andrographolide and AZGP1 intervention might be a promising strategy for improving the treatment benefit of CRC radiotherapy.

Keyphrases

dna damage response
cancer stem cells
randomized controlled trial
early stage
radiation therapy
locally advanced
cancer therapy
oxidative stress
radiation induced
risk assessment
drug delivery